NAS
MRNA icon

Nykredit A/S’s Moderna MRNA Stock Holding History

Nykredit A/S’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$913K Buy
+13,042
New +$675K ﹤0.01% 637

Other funds holding MRNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Nykredit A/S's MRNA Position: Q2 2026 in Review

Nykredit A/S opened a new position in Moderna (MRNA) in Q2 2026: 13,042 shares worth $913K. The stake represents ﹤0.01% of the portfolio and ranks #637 among its holdings.

614 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Nykredit A/S held 13,042 shares of Moderna worth $913K as of Q2 2026.
  • Moderna was a new Nykredit A/S position in Q2 2026.
  • Moderna made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #637 holding.
  • 614 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.